Eli Lilly & Co. has licensed worldwide rights to a small-molecule transcriptional regulator for the treatment of osteoarthritis to Transition Therapeutics. Toronto-based Transition says the drug, TT-601, has completed preclinical development and can enter the clinic next year. Under the agreement, Lilly has an option to reacquire rights to TT-601 after reviewing clinical results. The two firms struck a similar deal over TT-401, a diabetes drug candidate, in 2010. Last month Lilly exercised its option to reacquire that drug.